Pharming Group NV: RUCONEST (rhC1INH) marketed to treat acute Hereditary Angioedema (HAE) attacks with 100% response rate, no relapse, side effects, or plasma risk. Only product with future potential to be approved for both prophylaxis and treatment of attacks of HAE. Profitable, cash flow positive. Announced positive results from a ph2 study of RUCONEST in Contract-induced Nephropathy for patients receiving elective coronary angiography with or without a percutaneous coronary intervention (PCI). Pursuing new delivery formulations and larger indications for RUCONEST/rhC1INH, including 2019 clinical trials in pre-eclampsia and acute kidney injury, and development programs in Pompe and Fabry diseases.
Darwinweg 24
Leiden, 2333 CR

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.